On October 15th, the first production and manufacturing base of Boston Scientific China opened in the Life Blue Bay Pharmaceutical Characteristic Industrial Park in the Lingang New Area of the China (Shanghai) Pilot Free Trade Zone.
Boston Scientific is a globally leading innovative medical technology company. It is reported that the Boston Scientific Harbor Factory is equipped with leading laboratories in the medical technology industry, advanced production workshops and warehouses, as well as clean rooms that meet both Chinese and international standards. At the same time, the base has introduced industry-leading digital management and intelligent production systems such as enterprise management, manufacturing execution management, and product lifecycle management, which can achieve comprehensive visual management of the production base.
As an important component of Boston Scientific's comprehensive localization strategy in China, the Lingang Base will focus on the production of medical consumables and equipment in the future. This will enable Boston Scientific to achieve "independent production" in China, helping the company build a localization strategy layout covering all links of the entire industry chain, including trade, production, research and development, investment, and services, and provide more diversified innovative medical products for Chinese patients. Benefiting from the spillover effect of the CIIE, the factory will be the first to bring cardiovascular products after production.
Ann Bocheng, Global Executive Vice President and President of Medical Surgery and Asia Pacific Group at Boston Scientific, stated that the Lingang factory is an important step for Boston Scientific to establish long-term roots in China and integrate into the local medical industry chain in China. In the future, Boston Scientific will produce more high-quality innovative medical products here that meet the urgent needs of Chinese doctors and patients. This is also part of our long-term commitment to Chinese patients and the Chinese market.
Looking ahead, Zhang Jun, President of Boston Scientific Greater China, stated that the completion of the Lingang factory is an important milestone for Boston Scientific's development in China. Boston Scientific will leverage its port advantages to build a more agile and resilient supply chain, in order to respond more promptly, quickly, and stably to the needs of local doctors and patients. In the future, Boston Scientific will continue to increase its investment in China, actively cooperate with local suppliers, promote the transformation and upgrading of the local industrial chain with globally unified quality standards, and provide urgently needed innovative medical products for Chinese doctors and patients with high incidence diseases with new quality productivity.
It is reported that Life Blue Bay in Lingang New Area is an important carrier area of Shanghai's biopharmaceutical industry. In the five years since its establishment, Lingang New Area has focused on "precision diagnosis, precision drugs, precision surgery, health services and extension", gathering more than 100 cutting-edge leading biopharmaceutical enterprises, supporting innovative policy sources such as the Chinese Academy of Sciences, and striving to build a world-class biopharmaceutical industry development highland.